Perrigo Company Plc - Form 8-K Summary
Business Context and Reporting Period
Company: Perrigo Company Plc and Perrigo Finance Plc
Filing Date: December 5, 2014
Event: Entry into new material definitive credit agreements and termination of existing credit agreements to facilitate general corporate purposes and the proposed acquisition of Omega Pharma Invest NV.
Key Financial Metrics and Debt Structure
The filing details the establishment of new senior unsecured credit facilities replacing prior agreements. No revenue, profit, or cash flow data is provided in this specific filing.
- Revolving Facility: $1.0 billion total capacity.
- $600.0 million immediately available.
- $400.0 million available upon consummation of the Omega Pharma acquisition.
- Includes $50.0 million letter of credit sub-facility and $100.0 million swingline sub-facility.
- Maturity: 5 years from the effective date.
- 2-Year Term Loan Tranche: Up to $300.0 million.
- Maturity: December 18, 2015.
- 5-Year Term Loan Tranche: Up to €800.0 million.
- Includes a €300.0 million delayed draw facility contingent on the acquisition.
- Subject to annual amortization (10% for years 1-3, 12.5% for year 4, 15% for year 5).
- Maturity: 5 years from the effective date.
- Incremental Facilities: Uncommitted option to add up to $500.0 million in additional term or revolving loans.
- Interest Rates: Based on Alternate Base Rate or Eurodollar Rate plus an applicable margin tied to the Company's debt rating.
Material Changes Versus Prior Period
The Company terminated its existing Revolving Credit Agreement and Term Loan Credit Agreement (originally entered September 6, 2013, and amended November 19, 2014) effective December 5, 2014.
- Termination Terms: The existing agreements were terminated without any early termination penalty or prepayment premium.
- Administrative Agent Change: JPMorgan Chase Bank, N.A. replaced Barclays Bank PLC as the administrative agent for the lenders.
- Structure Change: The new agreements introduce a specific delayed draw tranche and acquisition-contingent revolving commitments not present in the prior structure.
Outlook, Risks, and Contingencies
Use of Proceeds: Funds will be used for working capital, general corporate purposes, and partially to finance the acquisition of Omega Pharma Invest NV, including related fees and expenses.
Contingencies:
- Availability of the $400.0 million revolving commitment and the €300.0 million delayed draw tranche is contingent upon the consummation of the Omega Pharma acquisition.
- Interest margins and commitment fees vary based on the Company's debt rating.
- The Company is obligated to pay "ticking interest" on unfunded portions of the delayed draw and acquisition revolving commitments starting January 5, 2015, until the acquisition closes or commitments are terminated.
Guarantees: The obligations of Perrigo Finance Plc under the new agreements are guaranteed by Perrigo Company Plc. All obligations are unsecured.
Investor Verification Checklist
- Verify the current debt rating of Perrigo Company Plc to determine applicable interest rate margins and commitment fees.
- Confirm the status and expected closing date of the Omega Pharma Invest NV acquisition, as this triggers significant portions of the new credit availability.
- Review the full text of the New Revolving Credit Agreement (Exhibit 10.1) and New Term Loan Credit Agreement (Exhibit 10.2) for specific covenants and default provisions.
- Monitor the Company's ability to service the new debt structure, particularly the amortization schedule of the 5-Year Tranche.